LOGIN  |  REGISTER

Integer to Present at Piper Sandler Healthcare Conference on Dec. 3, 2024

November 14, 2024 | Last Trade: US$119.96 1.81 -1.49

PLANO, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), will participate in the Piper Sandler 36th Annual Healthcare Conference, to be held Dec. 3 – 5 in New York City. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present Tuesday, Dec. 3, 2024, at 10:30 a.m. EST.

The presentation will be accessible via a live webcast. The link to the live webcast may also be accessed under “News & Events” on the Investor Relations section of the Integer website at investor.integer.net.

Learn more about Integer at www.integer.net.

About Integer®

Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, Integer is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.

Investor Relations:
Andrew Senn
This email address is being protected from spambots. You need JavaScript enabled to view it. 
763.951.8312
Media Relations:
Kelly Butler
This email address is being protected from spambots. You need JavaScript enabled to view it. 
214.618.4216
Terns Pharmaceuticals

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page